Qiu Kunyu, Young Isabella, Woodburn Blaide M, Huang Yirui, Anselmo Aaron C
Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Adv Healthc Mater. 2020 Mar;9(6):e1901643. doi: 10.1002/adhm.201901643. Epub 2020 Feb 20.
Microbe-based therapeutics (MBTs) are an emerging therapeutic modality for treating gastrointestinal infections and inflammatory bowel diseases. Current formulations for oral delivery of MBTs use capsules to achieve safe gastric transit, but oral formulations that control the spatiotemporal concentration of MBTs are yet to be developed, despite well-established connections between all therapeutics and their location, concentration, and distribution at sites of action. The development of a multi-functional polymer-based encapsulation system to formulate MBTs for enhanced storage and delivery through formulation of a model MBT, Lactobacillus casei ATCC393, is reported here. This approach enables the additive inclusion of excipients and polymers to grant specific functions, toward the development of a modular MBT platform. Through addition of established excipients, the formulation provides long-term storage of the encapsulated MBT. By adding higher molecular weight polymers, the release kinetics of the encapsulated MBTs can be modified. The inclusion of a mucoadhesive polymer significantly increases the adhesion force between the formulation and the intestinal tissue. Together, mucoadhesive and sustained release properties can be used to modulate the spatiotemporal concentration of MBTs. The formulation is compatible with standard oral capsules, thus maintaining existing clinical advantages of oral capsules while providing new functions from film encapsulation.
基于微生物的疗法(MBTs)是一种用于治疗胃肠道感染和炎症性肠病的新兴治疗方式。目前用于口服递送MBTs的制剂使用胶囊来实现安全的胃部转运,但是尽管所有疗法与其作用部位的位置、浓度和分布之间存在明确的联系,能够控制MBTs时空浓度的口服制剂仍有待开发。本文报道了一种基于多功能聚合物的封装系统的开发,该系统通过配制一种模型MBT——干酪乳杆菌ATCC393,来制备用于增强储存和递送的MBTs。这种方法能够额外添加辅料和聚合物以赋予特定功能,从而朝着模块化MBT平台的方向发展。通过添加既定的辅料,该制剂能够实现对封装的MBT的长期储存。通过添加更高分子量的聚合物,可以改变封装的MBTs的释放动力学。加入粘膜粘附聚合物可显著增加制剂与肠道组织之间的粘附力。粘膜粘附和缓释特性共同作用,可用于调节MBTs的时空浓度。该制剂与标准口服胶囊兼容,因此在保持口服胶囊现有临床优势的同时,通过薄膜封装提供新的功能。